Regional MRI Diffusion, White-Matter Hyperintensities, and Cognitive Function in Alzheimer's Disease and Vascular

Claudia Altamura1, Federica Scrascia2, Carlo Cosimo Quattrocchi3

  • 1Neurology Unit, Campus Bio-Medico University, Rome, Italy. c.altamura@unicampus.it.

Abstract

Insights

Higher brain water diffusivity in normal-appearing white matter is linked to microcirculatory issues and impacts cognitive functions like memory and reasoning in dementia patients.

Area of Science:

  • Neuroimaging and Neurology
  • White Matter Integrity
  • Dementia Pathophysiology

Background:

  • Increased brain water diffusivity in normal-appearing white matter (NAWM) is observed in cognitive impairment.
  • The cause of this diffusivity increase, whether neuronal damage or microvascular lesions, requires clarification.

Purpose of the Study:

  • Compare regional apparent diffusion coefficients (ADCs) in NAWM between Alzheimer's disease (AD) and vascular dementia (VaD) patients.
  • Investigate associations between NAWM ADCs, white-matter hyperintensity (WMH) burden, carotid atherosclerosis, and cognitive performance.

Main Methods:

  • Brain MRI to assess WMH volume and regional NAWM ADCs in 49 AD and 31 VaD patients.
  • Neuropsychological evaluations and carotid ultrasound (plaque severity, intima-media thickness) were performed.

Main Results:

  • No significant difference in NAWM ADCs between AD and VaD patients; WMH volume was higher in VaD.
  • Anterior corpus callosum ADC correlated with WMH volume; carotid intima-media thickness correlated with temporal ADC and WMH volume.
  • Poorer memory, constructional praxis, and abstract reasoning correlated with specific regional NAWM ADCs and WMH volume.

Conclusions:

  • Elevated regional ADCs in NAWM are associated with microcirculatory impairment, indicated by WMH volume.
  • Regional NAWM ADCs show differential associations with memory, constructional praxia, and abstract reasoning performance.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
672
Assessment of Diffusion and Perfusion01:17

Assessment of Diffusion and Perfusion

Understanding and evaluating diffusion and perfusion is critical in assessing a patient's respiratory and circulatory health. These processes play key roles in maintaining the body's internal environment, ensuring that tissues receive adequate oxygen while waste products are efficiently removed.
The Role of Diffusion in Respiration
Diffusion is the process by which molecules move from an area of higher concentration to an area of lower concentration. In the respiratory system, this...
2.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K